Tag: KZA

Kazia Therapeutics ASX KZA paxalisib EVT801 drug development clinical study

Kazia Therapeutics reports good half-year progress despite market challenges

Oncology-focused drug developer Kazia Therapeutics (ASX: KZA) has made good progress in the first six months of the year with pipeline assets paxalisib and EVT801 despite a challenging equity market f...
Kazia Therapeutics ASX KZA US FDA orphan drug designation paxalisib childhood brain cancer

Kazia Therapeutics collars US FDA orphan drug designation for paxalisib in a highly aggressive childhood brain cancer

Kazia Therapeutics (ASX: KZA) has collared orphan drug designation (ODD) from the United States Food and Drug Administration for its lead candidate paxalisib in treating a rare and highly aggressive c...
Kazia Therapeutics ASX KZA brain tumour positive data paxalisib childhood cancers

Kazia Therapeutics presents ‘positive data’ on paxalisib in childhood brain cancers

“Positive data” is being presented regarding the activity of Kazia Therapeutics’ (ASX: KZA) lead drug paxalisib in two forms of childhood brain cancers. The company is presenting the data via two p...
Kazia Therapeutics ASX KZA paxalisib study secondary brain tumours breast cancer

Kazia Therapeutics expands paxalisib study to include secondary brain tumours from breast cancer

Oncology-focused drug developer Kazia Therapeutics (ASX: KZA) is expanding a phase two study of its drug paxalisib in patients with brain metastases to include those starting from breast cancer. Th...
Kazia Therapeutics ASX KZA recruitment sites paxalisib global glioblastoma study GBM AGILE

Kazia Therapeutics adds recruitment sites to paxalisib arm of global glioblastoma study

Oncology-focused drug development company Kazia Therapeutics (ASX: KZA) has confirmed the multi-drug platform study GBM AGILE has opened recruitment to its paxalisib arm in Europe. GBM AGILE is a g...
Kazia Therapeutics ASX KZA at-the-market equity program Oppenheimer shares

Kazia Therapeutics establishes ‘at-the-market’ equity program

Oncology-focused biotechnology company Kazia Therapeutics (ASX: KZA) has established an ‘at-the-market’ (ATM) equity program, appointing US-based investment bank Oppenheimer & Co Inc as the sales ...
Kazia Therapeutics ASX KZA glioblastoma paxalisib phase II clinical oncology conference

Kazia Therapeutics completes phase II trial of paxalisib in glioblastoma

Kazia Therapeutics (ASX: KZA) is preparing to present the results of a phase II study evaluating its lead drug paxalisib in glioblastoma, which is the most aggressive form of brain cancer. The phas...
Kazia Therapeutics ASX KZA paxalisib childhood brain cancer paediatric tumour

Kazia Therapeutics’ paxalisib shows activity against rare childhood brain cancer in pre-clinical research

Kazia Therapeutics (ASX: KZA) has revealed pre-clinical data that its drug paxalisib demonstrates activity in two forms of childhood brain cancer where there is a very high unmet medical need. The ...
Kazia Therapeutics ASX KZA KZIA NASDAQ paxalisib metformin ketogenic diet glioblastoma

Kazia Therapeutics recruits first keto patient to phase II paxalisib study for treatment of glioblastoma

Oncology-focused drug development company Kazia Therapeutics (ASX: KZA) has recruited its first patient into a phase II study of investigational new drug paxalisib for the treatment of newly-diagnosed...
Kazia Therapeutics ASX KZA human trials lead cancer drugs brain paxalisib EVT801

Kazia Therapeutics advances human trials for lead cancer drugs during December quarter

Oncology-focused and clinical stage biotechnology company Kazia Therapeutics (ASX: KZA) has reported strong progress on the development of its lead drug candidates during the three months to 31 Decemb...
Kazia Therapeutics ASX KZA paxalisib drug granted fast track designation treatment glioblastoma brain cancer

Kazia Therapeutics’ paxalisib drug granted fast track designation for treatment of glioblastoma

Australian oncology-focused biotechnology company Kazia Therapeutics (ASX: KZA) has been granted Fast Track Designation by the US Food & Drug Administration for its lead drug paxalisib (formerly G...
Kazia Therapeutics ASX KZA paxalisib drug rare paediatric disease designation FDA

FDA grants Kazia Therapeutics’ paxalisib drug rare paediatric disease designation

Kazia Therapeutics (ASX: KZA) has been awarded Rare Pediatric Disease Designation (RPDD) for its lead drug paxalisib by the FDA for treating Diffuse Intrinsic Pontine Glioma (DIPG). RPDD status mea...
Kazia Therapeutics ASX KZA GBM AGILE glioblastoma brain cancer

Kazia Therapeutics’ lead brain cancer drug selected for international study

Kazia Therapeutics’ (ASX: KZA) lead drug GDC-0084 has been selected for use in GBM AGILE, which is an international academic-led glioblastoma study. According to Kazia, GBM AGILE is an adaptive pha...
Kazia Therapeutics ASX KZA oncology glioblastoma GDC-0084

Kazia Therapeutics reports positive early results from phase 2 glioblastoma trial using GDC-0084

Biotechnology company Kazia Therapeutics (ASX: KZA) has reported early data from a phase 2 study into the effects of lead candidate GDC-0084 on newly-diagnosed brain glioblastomas in adults has shown ...
Kazia Therapeutics ASX KZA Memorial Sloan Kettering Cancer Center radiotherapy clinical trial

Kazia Therapeutics unveils fresh clinical trial for its brain cancer drug candidate

Biotechnology company Kazia Therapeutics (ASX: KZA) has taken a definitive step towards proving the safety and efficacy of its investigational new drug GDC-0084, after announcing a “state of the art” ...
Kazia Therapeutics ASX KZA Glioblastoma brain cancer

Kazia Therapeutics commences clinical trial to redress the balance in glioblastoma treatment options

Glioblastoma is one of the most debilitating and deadly cancers, with limited treatment options that are currently effective for only a third of patients, says Kazia Therapeutics (ASX: KZA) CEO Dr Jam...

RECENT POSTS

STOCK SUMMARY

FOLLOW US

HOT TOPICS

TRENDING POSTS